1. - 1 -
CURRICULUM VITAE
Edwin B. Walker, Ph.D.
Scientific Director
Advanced Cytometry Solutions LLC
13563 NW Thompson Rd.
Portland, OR 97229
(503) 327-4976 (cell)
edwin.b.walker@gmail.com
Education/Training:
University of New Mexico School of Medicine, Ph.D. Awarded - 1982
Department of Pathology – Immunobiology Laboratory 09/77 - 06/82
Albuquerque, New Mexico (Advisor – Noel Warner, Ph.D.)
Postdoctoral Fellow 03/82 – 07/84
Experimental Pathology
Flow Cytometry Research and Development Group
Los Alamos National Laboratory
Los Alamos, New Mexico (Advisor - Carleton Stewart, Ph.D.)
Research/Academic Appointments:
Assistant Professor 08/84 – 12/89
Department of Medicine
Director, Flow Cytometry Resource Laboratory
Indiana University School of Medicine
Indianapolis, Indiana
Associate Professor 12/89 – 03/93
Department of Veterinary Pathobiology
School of Veterinary Medicine
Purdue University
West Lafayette, Indiana
Director, Immunopharmacology Laboratory 03/93 – 05/99
Director, Flow Cytometry Laboratory
Product Development Department
RIBI ImmunoChem Research, Inc.
Hamilton, Montana
Chief, Laboratory of Immunological Monitoring 01/00 – 01/12
Robert W. Franz Cancer Research Center
Earle A. Chiles Research Institute
Providence Cancer Center
Portland, Oregon
Senior Scientist 01/12 – 11/12
Robert W. Franz Cancer Research Center
Earle A. Chiles Research Institute
Providence Cancer Center

2. - 2 -
Scientific Director 01/13 - present
Advanced Cytometry Solutions LLC
13563 NW Thompson Rd.
Portland, OR 97229
Professional Societies:
American Association of Immunologists
International Society for Analytical Cytology
Society for Immunotherapy of Cancer
Consultantships:
Senior Consulting Scientist (1988 – 2004) – The Laboratory for Diagnostic and Analytical
Cytometry (LDAC). 7750 Zionsville Rd., Indianapolis, Indiana 46268.
Senior Consulting Scientist (5/99 – 1/2004) – Endobiologics Inc.
7151 Kestrel Dr., Missoula, Montana 59808
Patents:
Walker, EB, and Sowell, G. Methods of Modulating Dendritic Cells Using Adjuvants. Serial No.:
60/220,081; Filed: July 21, 2000.
Brendan Curti, Magdalena Kovacsovics-Bankowski, Edwin Walker, Joshua Walker, Andy
Weinberg. Cancer Treatment and Monitoring Methods Using ox40 Agonists (WO2013119202
A1); Filed: Feb.6,2012.
Honors:
Sigma XI Scientific Honor Society, Recipient of the 1980 New Mexico Chapter, Outstanding
Graduate Student Research Award
Reticuloendothelial Society, Recipient of the 1980 President’s Award
Becton Dickinson Postdoctoral Fellow, 1982-1984
Showalter Trust Foundation Fellow, 1989-1990
Research Support:
Active Funding from Contract Research Programs:
Bristol-Myers Squibb contracted with the Providence Cancer Center to perform polychromatic flow
cytometry immunomonitoring studies of patient samples from five clinical trials in 2012. All funding
from these studies remained at Providence Cancer Center upon leaving to become the Scientific
Director at Advanced Cytometry Solutions LLC in 2013.
NCIC 202: IL-21 vs Dacarbazine (DTIC) in Patients with Metastatic or Recurrent Melanoma. Budget:
$37,061 (E.B. Walker PhD )
BMS CA209-009: Dose Escalation Study of Anti-PD-1 mAb in Patients with Metastatic Renal Cell
Carcinoma (RCC). Budget: $183,402 (E.B. Walker PhD )
BMS CA220-007: IL-21 in Combination with Ipilimumab in Patients with Unresectable Stage III or
Stage IV Melanoma. Budget: $651,499 (E. B. Walker PhD )
BMS CA220-008: Phase I Dose-Escalation Study of IL-21 in Combination with Anti-PD-1 in Patients
with Advanced Metastatic Solid Tumors. Budget: $295,079 (E.B. Walker PhD )

3. - 3 -
BMS CA 209-038: Phase I Dose-Escatlation Study of Anti-PD-1 in Patients with Unresectable Stage
III or IV Melanoma. Budget: $203,703 ( E. B. Walker PhD )
Completed:
1 K22 CA127739-01A1 (Poehlein) 04/01/08-03/31/11 0.5 calendar
NIH $118,849
Characterizing and Regulating Tumor-induced Regulatory T Cells
The major goals of this project are:1) To characterize the kinetics of expression and role for three
recently identified novel markers for iTreg, CD81, Amphiregulin and Prostaglanding Receptor EP3 in
the RLM model, 2) To investigate whether CD81, Amphiregulin and Prostaglanding Receptor EP3
can be exploited to manipulate the number, phenotype and/or functional activity of iTreg in vivo, 3)
To investigate how histologically distinct tumors induce iTreg that are capable of inhibiting the
generation of melanoma-specific effector T cells and thereby suppress anti-tumor immunity.
5 R01 CA119123-03 (Fox) 06/01/06-04/30/10 1.2 calendar
NIH $172,353
Exploiting Lymphopenia to Augment the Adoptive Immunotherapy of Melanoma Patients
The major goals of this project are: 1) To determine whether reconstitution with CD25-depleted
PBMC increases the tumor-specific T cell response of patients made lymphopenic by treatment with
cyclophosphamide and fludarabine, and vaccinated with autologous tumor and GM-CSF (pick-the-
winner). 2) To characterize changes in the effector, effector/memory and central memory phenotype
of tumor-specific T cells of patients treated on clinical trials proposed in aims 1 and 4. 3) To
characterize the regulatory T cell population in the peripheral blood prior to and following induction
of lymphopenia and reconstitution. 4) T perform an adoptive immunotherapy trial with T cells
generated using the winning strategy identified in aim 1.
5 R21 CA123864-02 (Urba) 06/01/08-05/31/10 0.6 calendar
NIH $225,000
Clinical Trial of DRibble Vaccine in NSCLC
The goals of this project are: 1) Perform a pilot clinical trial to evaluate the feasibility of producing a
DRibble vaccine in patients with stage IIIB or IV NSCLC using malignant pleural effusion or
subcutaneous metastases as a source of autologous cancer cells for vaccine generation, and 2)
Evaluate the immunologic efficacy of the vaccine and docetaxel treatment by in vitro immune
monitoring.
2007-014 (Urba) 03/01/08-06/30/09 0.9 calendar
Kuni Foundation $125,000
Clinical Trial of DRibble Vaccine in NSCLC
The major goals of this project are: 1) Perform a pilot clinical trial to evaluate the safety and
feasibility of DRibble vaccine in patients with NSCLC, and 2) Evaluate the immunologic efficacy of
the vaccine and docetaxel treatment by in vitro immune monitoring.
Department of Defense (PC020094), “Development of effective Immunotherapy for Prostate Cancer
Patients,” 1/1/03-12/31/05; Bernard A Fox, PhD – PI
Edwin B. Walker, Ph.D. (15%): Co-Investigator
Specific Aims: 1) Evaluate the safety of combined allogeneic prostate GVAX vaccination,
chemotherapy with cyclophosphamide +/- fludarabine and hematopoietic reconstitution in patients
with advanced hormone-refractory prostate cancer (HRPC). 2) Explore the effects of different
chemotherapy regimens on the immune response of allogeneic prostate GVAX vaccinated and
reconstituted lymphopenic patients with HRPC. 3) Evaluate in vitro sensitization methods for their
capacity to expand tumor vaccine-specific CD4+ and CD8+ T cells from the peripheral blood and to

4. - 4 -
determine whether the degree of lymphopenia inversely correlates with the expansion of tumor-
specific CD4 and CD8 T cells.
NIH (1 R21 CA101325-01A1), “GP100 Peptide Immunization After Lymphocyte Depletion,”
9/1/03-8/31/05. Walter J. Urba, MD, PhD – PI
Edwin B. Walker, Ph.D. (15%): Co-Investigator.
Dr. Walker as Chief of the immunological Monitoring Lab (IML), was responsible for all the immune
monitoring for the clinical Trial. His lab was responsible for the receipt, processing, registration and
cryopreservation of all research samples collected during the protocol. He supervised the
performance of the ELISPOT, tetramer and intracellular cytokine assay by IML personnel, and was
responsible for the generation of the autologous dendritic cells used in the immunologic assays. He
was primarily responsible for interpretation and quality control of all immunological monitoring
assays, and worked with the other investigators in preparation of manuscripts, presentations and
future clinical trial design.
NIH (1RO1 CA109563-01), “Clinical Development of Anti-OX40 and OX40L”
7/1/04-6/30/09. Brendan Curti, MD – PI
Edwin B. Walker, PhD (20%)
Specific Aims: 1) Define a well-tolerated dose of anti-OX40 for use in future clinical trials in humans.
2) Characterize the primary and recall immune responses to reporter antigens after anti-OX40
treatment. 3) Produce a soluble form of the human OX40 ligand that contains the receptor-binding
domain and matches or exceeds the biologic activity of the OX40 agonist antibody.
NIH (1 R21 CA099265-01A2), “Peptide Booster Vaccination in A2+ Melanoma Patients”
2/1/04-1/31/06. Walter J. Urba, MD, PhD – PI
Edwin B. Walker, PhD (25%): Co-Investigator
Specific Aims: 1) Determine the kinetics and duration of the memory/effector CD8+ T-cell response
to modified and native gp100 peptide antigens after boosting vaccination with modified gp100 (209-
2M) peptide. 2) Determine the potency of the memory/effector CD8+ T cell response to modified and
native gp100 peptide antigens before and after boosting vaccination. 3) Characterize the cell
surface phenotype and function of gp100 tetramer+ memory/effector CD8+ T cells before and after
boosting vaccination.
NIH (1RO1 CA107243-01), “TLR-Mediated DC Activation and Immune Reconstitution”
4/1/04-3/31/09. Hong-Ming Hu, PhD – PI
Edwin B. Walker, PhD (5%)
Specific Aims: The goals of this proposal are: 1) Define the condition under which DC can be
activated and matured that will lead to maximal proliferative response of naïve Pmel-1 CD8+ T cells.
2) Determine whether optimally conditioned TP-DC will mediate tumor regression in RLM. 3)
Determine the fate of gp100-specific CD8+ T cells derived from Pmel-1 TCR transgenic mice in
vaccinated RLM and how CD4 help affects their expansion and function.
NIH (1 ro1 ca 39925) “Mechanisms of Gamma Interferon Regulation of Ia Antigens,” 1/1/84 –
12/31/87; 3 year total = $228,144; Edwin B. Walker, Ph.D. - PI.
NIH (1 U01 AI 25859 SCR) “Indiana AIDS Clinical Research Group,” 10/1/87 – 8/31/92;
Robert B. Jones, M.D. – PI
Edwin B. Walker, Ph.D. – Co-Investigator
Year 1 = $1,305,557; 5 year total = 6.1 million. First year of E.B. Walker’s funding - $156,875.
Project title: “Multiple Parameter Flow Cytometry Analysis in AIDS.” Five year total of E.B. Walker’s
funding - $892,151. Support from this program project grant ended January 1, 1990, upon accepting
the position at Purdue University.
Showalter Trust Grant. “Immunophenotyping and Functional Analysis of the Discrete Natural Killer
(NK) Cell Progenitor Subpopulation in Man Which Develops Into Lymphokine Activated killer (LAK)
Cells.” $40,000 for one year beginning July 1,1990; Edwin B. Walker, Ph.D. – PI.

5. - 5 -
Publications:
1. Warner, NL, Burcheil, SW, Walker, EB, Richey, JB, Leary, J, McGlaughlin, S. Characterization
of murine B cell lymphomas and macrophage tumors by flow microfluorometry and Functional
assays. In: Immunobiology and Immunotherapy of Cancer, Elsevier, North Holland. 1979.
2. Walker, EB, Van Epps, DE, Warner, NL. Macrophage Chemiluminescence. In: Manual of
Macrophage Methodology, Marcel Dekkar, Inc., New York. 1981.
3. Warner, NL, Cheney, R, Daley, M, Lanier, L, Walker, EB. Intratumor differentiation
heterogeneity in murine hematopoietic tumors. In: Maturation Factors in Cancer. Raven Press,
New York. 1981.
4. McKean, DJ, Infante, AK, Nilson, A, Kimoto, M, Fathman, DG, Walker, EB, Warner, NL. Major
histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B
lymphocyte tumor cells. J Experimental Med. 154:1419. 1981.
5. Warner, NL, Lanier, LL, Walker, EB, Stewart, CC, Wood, G, Balch, C. Hematopoietic tumors:
normal or abnormal models of leukocyte differentiation. In: Hybridomas and Cellular
Immortality. Plenum Press, New York. 1982.
6. Lanier, LL, Walker, EB, Richie, R-R, Warner, NL. Murine hematopoietic cell tumors: models for
analysis of cellular differentiation. In: B and T Cell Tumors - Biological and Clinical Aspects.
UCLA Symposium on Molecular and Cellular Biology. Academic Press, New York. 1982.
7. Wharton, W, Walker, EB, Stewart, C. Growth regulation by macrophage. In: Proceedings of the
Ninth Reticuloendothelial Society Conference. Plenum Press, New York, 1982.
8. Walker, EB, Lanier, L, Warner, NL. Concomitant induction of the cell surface expression of Ia
determinants and accessory cell function by a murine macrophage tumor cell line. J
Experimental Medicine. 155:629. 1982.
9. Walker, EB, Lanier, L, Warner, NL. Characterization and functional properties of tumor cell lines
in accessory cell replacement assays. J Immuno. 128:852. 1982.
10. Walker, EB, Warner, NL, Chesnut, R, Kappler, J, Marrack, P. Antigen specific, I region-
restricted interactions in vitro between tumor cell lines and T-cell hybridomas. J Immuno.
128:2164. 1982.
11. Stewart, CC, Walker, EB, Warner, NL, Walker, W. Mononuclear phagocyte proliferation and
differentiation. Mononuclear Phagocyte Biology. Marcel Dekker, Inc., New York. 1984.
12. Stewart, CC, Walker, EB, Warner, NL, Walker, W. Clonal analysis of bone marrow macrophage
cultures. In: Proceedings of the Fourth Leiden Conference on Mononuclear Phagocytes.
Martinues Nighoff, Netherlands. 1984.
13. Walker, EB, Maino, VB, Sanchez-Lanier, M, Warner, N, Stewart, C. Murine gamma interferon
activates the release of a macrophage-derived, Ia-inducing factor which transfers Ia inductive
capacity. J Experimental Medicine. 159:1532-1537. 1984.
14. Walker, EB, Akporiaye, ET, Warner, NL, Stewart, CC. Characterization of subsets of bone
marrow defived macrophage by flow cytometry analysis. J Leukocyte Biology. 37:121-136.
1985.
15. Kelly, LW, Brief, S, Westley, HJ, Novakafski, J, Bechtel, PJ, Simon, J, Walker, EB. GH3 pituitary
adenoma cells can reverse thymic aging in rats. Proceedings of the National Academy of
Science. 83:5663-5667. 1986.
16. Walker, EB, and Leemhuis, T. The same cloned murine B Lymphoma cell lines can be
selectively induced to release either Interleukin-1 or Interleukin-2 like factor activity. J
Lymphokine Research. 6:71-81. 1987.
17. Kelley, KW, Brief, S, Westley, HJ, Novakafski, H, Bechtel, PJ, Simon, J, Walker, EB. Hormonal
regulation of the age-associated decline in immune function. Annals of the New York Academy
of Science. 496:91. 1987.
18. Boswell, HS, Burgess, JS, Srivastava, A, Podgett, G, Walker, EB, Geib, RW. Cellular control of
in vitro progression of murine myeloid leukemia: transformation accompanies acquisition of
growth factor and stromal cell independence. Leukemia. 1:765-771. 1987.
19. Li, Lu, Walker, DE, Broxmeyer, HE, Hoffman, R, Wen Hu, Walker, EB. Characterization of adult
human marrow hematopoietic progenitors highly enriched by two color cell sorting with MY 10
and major histocompatibility class II monoclonal antibodies. J Immuno. 139:1823-1829. 1987.
20. Park, MM, and Walker, EB. Characterization of a T cell subset prevalent in immunoregulatory
disorders in humans. Cellular Immunology. 111:265-272. 1988.

6. - 6 -
21. Walker, EB, Leemhuis, T, Roeder, W. Murine B Lymphoma cell lines release functionally active
IL-2 after stimulation by Staphylococcus aureus. J Immuno. 140:859-865. 1988.
22. Downing, J, Martinez-Valdes, H, Elizondo, RS, Walker, EB, Taylor, M. Hyperthermia in humans
enhances interferon-gamma synthesis and alters the peripheral lymphocyte population. J of
Interferon Research. 8:139-146. 1988.
23. Li, Lu, Srour, EF, Warren, DJ, Walker, D, Graham, DD, Walker, EB, Jansen, J, Broxmeyer, JE.
Enhancement of release of granulocyte- and granulocyte-macrophage Colony-stimulating
factors from phytohemagglutinin-stimulated, sorted subsets of human T lymphocytes by
recombinant human tumor necrosis factor-alpha. J lmmuno. 141:201-207. 1988.
24. Brandt, J, Lu, L, Walker, EB, Hoffman, R. Detection of human hematopoietic progenitor cells
capable of forming blast cell containing colonies in vitro. Advances in Experimental Medicine
and Biology. 241:165-173. 1988.
25. Srour, EF, Walker, EB, Walker, DE, Jansen, J. Functional and phenotypical studies of the leu-4
(CD3)+, leu-1 (CD5)- lymphocyte. Clinical and Experimental Immunology. 73:34-39. 1988.
26. Geissler, K, Tricot, G, Leemhuis, T Walker, EB, Broxmeyer, HE. Differentiation-inducing effect of
recombinant human tumor necrosis factor alpha and gamma-interferon in vitro on blast cells
from patients with acute myeloid leukemia and myeloid blast crisis of chronic myeloid leukemia.
Cancer Research. 49:3057-3062. 1989.
27. Boswell, JS, Mochizuki, D, Burgess, GS, Gillis, S, Walker, EB, Williams, DE. A novel mast cell
growth factor (MCGF-3) produced by marrow adherent cells that synergizes with interleukin-3
and interleukin-4. Experimental Hematology. 18:794. 1990.
28. Schnizlein-Bick, CT, Magier, MR, Jones, RB, Fife, KH, Katz, BP, Walker, EB. Differences
among mononuclear cell populations in HIV seropositive or seronegative homosexual and
heterosexual males as determined by four-color flow cytometry. J Acq Immune Deficiency
Syndromes (AIDS). 3: 747-756. 1990.
29. Walker, EB. Four color flow cytometry. In: Handbook of Flow Cytometry Methods. International
Society for Analytical Cytology and Purdue University Cytometry Laboratories. 1990.
30. Tsonis, PA, and Walker, EB. Cell populations synthesizing cartilage proteoglycan core protein
in the early chick limb bud. Biochemica, Biophysica Research Communications. 174(2):688-695.
1991.
31. Hustmyer, FG, Walker, EB, Xiao-Peng, Y, Girasole, G, Sakagarni, Y, Peacock, M, Manolagas,
SC. Cytokine production and surface antigen expression by peripheral blood mononuclear cells
in postmenopausal osteoporosis. Journal of Bone and Mineral Research. 8(1):51. 1993.
32. Clemo, FAS, Crabtree, W, Walker, EB, DeNicola, DB. Comparison of image analysis and flow
cytometric measurements of DNA content of canine transitional cell carcinomas. Analytical and
Quantative Cytology and Histology. 15(6):418-426. 1993.
33. Clemo, FAS, DeNicola, DB, Carlton, WW, Morrison, WB, Walker, EB. Flow cytometric DNA
ploidy analysis in canine transitional cell carcinoma of urinary bladder. Veterinary Pathology.
31(2):207-215. 1994.
34. de Riese, WT, de Riese, C, Ulbright, TM, Walker, EB, Messemer, J, Jones, JA, Reister, T,
Albers, P, Allhoff, EP, Foster, RS. Flow Cytometric and quantitative histologic parameters as
prognostic indicators for occult retroperitoneal disease in clinical - Stage - I non-seminomatous
testicular germ cell tumors. Int J Cancer. 57(5): 628-633. 1994.
35. de Riese, WT, Albers, P, Walker, EB, Ulbright, TM, Crabtree, WN, Reister, T, Foster, RS,
Donohue, JP. Predictive parameters of biologic behavior of early stage non-seminomatous
testicular germ cell tumors. Cancer. 74(4):1335-1341. 1994.
36. Albers, P, de Riese, WT, Walker, EB, Ulbright, TM, Crabtree, WN, Reister, T, Foster RS,
Donohue, JP. Predictive parameters in biologic assessment of low-stage retroperitoneal node
dissection. World J Urol. 12(3): 120-4. 1994.
37. de Riese, WT, Walker, EB, de Riese, C, Ulbright, TM, Crabtree, WN, Messemer, J, Jones, JA,
Hinkel, A, Foster, RS, Donohue, JP, et al. Quantitative DNA measurement by flow cyometry and
image analysis of human nonseminomatous germ cell testicular tumors. Urol Res. 22(4):213-20.
1994.
38. Clemo, FAS, DeNicola, DB, Carlton, WW, Walker, EB, Morrison, WB. Immunoreactivity of
canine transitional cell carcinoma of the urinary bladder with monoclonal antibody to tumor
associated glycoprotein 72. Veterinary Pathology. 32(2):155-161. 1995.

7. - 7 -
39. Zhao, L, Griggs, LN, Elliott, GT, Walker, EB. Effects of nitric oxide and monophosphoryl lipid A
on leukocyte transmigration across endothelial cell monolayers. Int J Immunotherapy. XIV(2):57-
67. 1997.
40. Pfau, JC, Walker, EB, Card, GL. A comparison of the effects of lipopolysaccharide and
ceramide on arachidonic acid metabolism in THP-1 monocytic cells. Cellular Immunol.
186(2):147-153. 1998.
41. Phau, JC, Walker, EB, Card, GL. Monoclonal antibodies to CD45 modify LPS-induced
arachidonic acid metabolism in macrophages. Biochemica et Biophysica Acta. 1492:212-220.
2000.
42. Elliott, GT, Sowell, CG, Walker, EB, Weber, PA, Moore, J, Gross, GJ. The novel glycolipid RC-
552 attenuates myocardial stunning and reduces infarct size in dogs. J Mol Cell Cardio.
32(7):1327-39. 2000.
43. Meijer, SL, Dols, A, Hu, H-M, Jensen, S, Poehlein, CH, Chu, Y, Winter, H, Yamada, J, Moudgil,
T, Wood, WJ, Doran, T, Justice, L, Fisher, B, Wisner, P, Mehrotra, R, Rosenheim, S, Weinberg,
AD, Bright, R, Walker, EB, Puri, R, Smith II, JW, Urba, WJ, Fox, BA. Immunological and
Molecular Analysis of the Sentinel Lymph Node: A Potential Approach to Predict Outcome,
Tailor Therapy, and Optimize Parameters for Tumor Vaccine Development. J. Clin. Pharmacol.
41:81S-94S. 2001.
44. Walker, EB and Disis, ML. Monitoring immune responses in cancer patients receiving tumor
vaccines. International Reviews of Immunology. 22:283-319. 2002.
45. Smith, JW, Walker, EB, Fox, BA, Haley, D, Wisner, KP, Doran, T, Fisher, B, Justice, L, Wood,
W, Vetto, J, Maecker, H, Dols, A, Meijer, S, Hu, HM, Romero, P, Alvord, WG, Urba, WJ.
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide
induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 21:1562-1573. 2003.
46. Dols, A, Smith, J, Meijer, SL, Fox, BA, Hu, HM, Walker, EB, Rosenheim, S, Moudgil, T, Doran,
T, Wood, W, Seligman, M, Alvord, WG, Schoof, D, Urba, WJ. Vaccination of Women with
Metastatic Breast Cancer, Using a Costimulatory Gene (CD80)-Modified, HLA-A2-Matched,
Allogeneic, Breast Cancer Cell Line: Clinical and Immunological Results. Human Gene Therapy.
14:000-000:1-7. 2003.
47. Hu, HM, Dols, A, Meijer, S, Floyd, K, Walker, EB, Urba, W, Fox, B. Immunological monitoring of
patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer
complexes. J Immunother. Vol 27(1):48-59. 2004.
48. Walker, EB, Haley, D, Miller, W, Floyd, K, Wisner, KP, Sanjuan, N, Maecker, H, Romero, P, Hu,
HM, Alvord, WG, Smith II, JW, Fox, BA, Urba, WJ. gp100209-2M Peptide Immunization of HLA-
A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and
Long-Term Memory CD8+ T Cells. J. Clinical Cancer Res. 10:668-680 January 15, 2004.
49. Ma, JP, Poehlein, CH, Jensen, SM, LaCelle, MG, Moudgil, TM, Ruttinger, D, Haley, D.,
Goldstein, MJ, Smith II, JW, Curti, B, Ross, H, Walker, EB, Hu, HM, Urba, WJ, Fox, BA.
Manipulating the Host Response to Autologous Tumour Vaccines. Dev Biol; Development of
Therapeutic Cancer Vaccines. 116:93-104. 2004.
50. Hahn, T, Alavarez, I, Kobie, JJ, Ramanathanpuram, L, Dial, S, Fulton, A, Besselsen, D, Walker,
EB, Akporiaye, ET. Short-term dietary administration of celecoxib enhances the efficacy of
tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int J Cancer.
118(9):2220-31. 2006.
51. He, H, Wisner, P, Yang, G, Hu, H, Haley, D, Miller, W, O’Hara, Alvord,WG, Clegg, CH, Fox, BA,
Urba, WJ, Walker, EB. Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor
immunity and long-term curative effects in a murine melanoma tumor model. J Translation
Medicine. 4:24. 2006.
52. Petrausch, U, Haley, D, Miller, W, Floyd, K, Urba, WJ, Walker, EB. Polychromatic flow
cytometry: A rapid method for the reduction and analysis of complex multiparameter data.
Cytometry Part A. 69(12):1162-1173. Dec. 2006.
53. Ruttinger D, Rui, L, Poehlein, CH, Haley, D, Walker, EB, Hu, HM, Fox, BA. Increased
susceptibility to immune destruction of B16BL6 tumor cells engineered to express a novel pro-
Smac fusion protein. J Immunotherapy. 31(1)43-51.2007.
54. Meijer, SL, Dols, A, Jensen, SM, Hu, HM, Miller W, Walker, EB, Romero, P, Fox, BA, Urba, WJ.
Induction of circulating tumor-reactive CD8+ T cells following vaccination of melanoma patients
with the gp100209-2M peptide. J Immunotherapy. 30(5):533-43. 2007.

8. - 8 -
55. Walker EB, Haley D, Petrausch U, Floyd K, Miller WL, Sanjuan N, Alvord G, Fox BA, Urba WJ.
Phenotype and Functional Characterization of Long-Term gp100-Specific Memory CD8+ T Cells
in Disease-Free Melanoma Patients Before and After Boosting Immunization. J Clin Can Res.
14(16):5270-83. 2008.
56. Walker EB, Miller WL, Haley D, Floyd K, Curti B, Urba WJ. Characterization of the Chass I-
Restricted gp100 Melanoma Peptide-stimulated Primary Immune Response in Tumor-Free
Vaccine-draining Lymph Nodes and Peripheral Blood. Clin Can Res.15(7):2541-2551.2009.
57. Thompson JA, Assmann I, Haley D, Moudgil TL, Jensen SM, Poehlein CH, Hu H, Walker EB,
Sacks B, Hege K, Curti B, Urba WJ, Fox BF. Increased lymphopenia results in higher
percentages of FoxP3+ T cells in patients reconstituted by PBMC adoptive transfer and
vaccinated. J. Immunol. 182: 41.36. Apr 2009.
58. Petrausch U, Poehlein CH, Jensen SM, Twitty C, Thompson JA, Assmann I, Puri S, LaCelle
MG, Moudgil T, Maston L, Friedman K, Church S, Cardenas E, Haley DP, Walker EB,
Akporiaye ET, Weinberg AD, Rosenheim S, Crocenzi TS, Hu HM, Curti BD, Urba WJ, Fox BA.
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their
inhibitory effects. Curr Mol Med. Aug;9(6):673-82. 2009.
59. Poehlein, CH, Haley, D, Walker, EB, Fox, BA: Depletion of tumor-induced regulatory T cells
prior to reconstitution rescues enhanced priming of tumor-specific, therapeutic effector T cells in
lymphopenic hosts. Eur J Immunology.39:3121-3133, 2009. PMCID: PMC2850261 (avail
2010/11/01).
60. Petrausch U, Jensen SM, Twitty C, Poehlein CH, Haley DP, Walker EB, Fox BA. Disruption of
TGF-β Signaling Prevents the Generation of Tumor-Sensitized Regulatory T cells and
Facilitates Therapeutic Antitumor Immunity. J Immunol.183:3682-3689.2009.PMCID:
PMC2850273
61. Siebert, J., S. Puri, J.A. Thompson. T. Moudgil, I. Assmann, T. Ratzow, S. Jensen, M.G.
Lacelle, D. Haley, C. H. Poehlein, E. B. Walker, N. Sacks, K. Hege, H.-M. Hu, B. D. Curti, W. J.
Urba, and B. A. Fox. 2009. A Data Analysis Method for Identifying Autoantibody Biomarkers in
Cancer Patients Following Immunotherapy. J. Immunother 32:984
62. Puri, S., J. A. Thompson, J. C. Siebert, T. Moudgil, D. Haley, C. H. Poehlein, E. B. Walker, N.
Sacks, K. Hege. H. –M. Hu, C. Bifulco, W. J. Urba, B. D. Curti, and B. A. Fox 2010. Antibody
Response Following Immunotherapy Identifies Novel Antigens that are Expressed by Circulating
Tumor Cells in Men with Hormone-Refractory Prostate Cancer. J. Immunother 33:908
63. Wang LX, Li Y, Yang G, Pang PY, Haley D, Walker EB, Urba WJ, Hu HM. CD122+ CD8+
Treg cells suppress vaccine-induced antitumor immune responses in lymphodepleted mice.
Eur. J. Immunol. 40:1-13. 2010. PMCID: 20186876
64. Siebert, JC, Wang L, Haley DP, Romer A, Zheng, B, Munsil, W, Gregory, KW, Walker EB.
Exhaustive expansion: A novel technique for analyzing complex data generated by higher-
order polychromatic flow cytometry experiments.J Trans Med. 8:106. 2010 DOI
10.1186/1479-5876-8-106 PMCID: 21034498
65. Siebert, JC, Walker EB. Monitoring Cytokine Profiles During Immunotherapy.
Immunotherapy. 2(6):799-816. 2010. PMCID: 21091113
66. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden MR, Li Y, Puri S,
Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM,
Urba WJ, Weinberg AD, Curti B, Fox BA. Signaling Through OX40 Enhances Antitumor
Immunity. Semin Oncol. 2010. Oct;37(5):524-32. PMCID: 21074068
67. Hahn, T, Bradley-Dunlop D, Hurley LH, Von-Hoff D, Gately S, Disis ML, Lu H, Penichet ML,
Besselsen DG, Cole, BB, Meeuwsen, T, Walker EB, Akporiaye, ET. The vitamin E analog,
alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against
HER2/neu-expressing breast cancer. BMC Cancer. 2011. Nov.11:471. PMID: 22044845
68. Triplett TA, Curti BD, Bonafede PR, Miller WL, Walker EB, Weinberg AD. Defining a
functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG
Eur J Immunol 2012 42(7):1893-1905. PMID: 22585674.
69. Seung SK, Curti BD, Crittenden MR, Walker EB, Coffey T, Siebert JC, Miller W, Payne R,
Glenn L, Bageac A, Urba WJ. Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-
2 – Tumor and Immunological Responses. Sci Transl Med 2012 Jun 6;4(137):137ra74.

9. - 9 -
70. van de Ven R, Haley D, Walker EB, Fountain C, Douglas J, Wood W, Yu K, Aliabadi S, Fox
B, Hu HM, de Gruijl T, and Urba W. Interrogating BDCA3+ dendritic cells in human tumor-
draining lymph nodes. J Immunology, 188: 127.43, 2012.
71. Curti BD, Kovacsovics-Bankowski M, Morris N, Walker EB, Chisholm L, Floyd K, Walker J,
Meeuwsen T, Fox BA, Modgil T, Miller W, Haley D, Coffey T, Fisher B, Delanty-Miller L,
Rymarchyk N, Kelly T, Crocenzi T, Bernstein E, Sanborn R, Urba WJ, Weinberg AD. OX40 is a
potent target for immune stimulation in late stage cancer patients. Cancer Research Nov 2013,
73(24), 1-10. PMID 24177180